DK4007777T3 - Car-t-celler mod bcma til behandlingen af myelomatose - Google Patents

Car-t-celler mod bcma til behandlingen af myelomatose Download PDF

Info

Publication number
DK4007777T3
DK4007777T3 DK20757544.0T DK20757544T DK4007777T3 DK 4007777 T3 DK4007777 T3 DK 4007777T3 DK 20757544 T DK20757544 T DK 20757544T DK 4007777 T3 DK4007777 T3 DK 4007777T3
Authority
DK
Denmark
Prior art keywords
myelomatosis
car
treatment
cells against
against bcma
Prior art date
Application number
DK20757544.0T
Other languages
English (en)
Other versions
DK4007777T5 (da
Inventor
Antonio Beatriz Martín
Ispizua Álvaro Urbano
Amill Lorena Pérez
Rodriguez Guillermo Suñe
Otero Manel Juan
Original Assignee
Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer Frcb Idibap
Hospital Clinic Barcelona
Univ Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer Frcb Idibap, Hospital Clinic Barcelona, Univ Barcelona filed Critical Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer Frcb Idibap
Application granted granted Critical
Publication of DK4007777T3 publication Critical patent/DK4007777T3/da
Publication of DK4007777T5 publication Critical patent/DK4007777T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
DK20757544.0T 2019-08-02 2020-08-03 Car-t-celler mod bcma til behandlingen af myelomatose DK4007777T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382673 2019-08-02
PCT/EP2020/071831 WO2021023721A1 (en) 2019-08-02 2020-08-03 Car t-cells against bcma for the treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
DK4007777T3 true DK4007777T3 (da) 2024-01-15
DK4007777T5 DK4007777T5 (da) 2024-08-05

Family

ID=67658496

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20757544.0T DK4007777T5 (da) 2019-08-02 2020-08-03 Car-t-celler mod bcma til behandlingen af myelomatose

Country Status (18)

Country Link
US (1) US12509525B2 (da)
EP (2) EP4272837A3 (da)
JP (1) JP7729561B2 (da)
AU (1) AU2020325690A1 (da)
CA (1) CA3148930A1 (da)
DK (1) DK4007777T5 (da)
ES (1) ES2971033T3 (da)
FI (1) FI4007777T3 (da)
HR (1) HRP20240037T1 (da)
HU (1) HUE064890T2 (da)
LT (1) LT4007777T (da)
PL (1) PL4007777T3 (da)
PT (1) PT4007777T (da)
RS (1) RS65094B1 (da)
SI (1) SI4007777T1 (da)
SM (1) SMT202400013T1 (da)
WO (1) WO2021023721A1 (da)
ZA (1) ZA202201166B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4475896A1 (en) * 2022-02-09 2024-12-18 Hadasit Medical Research Services&Development Ltd. Anti-bcma car to target immune-related disorders, compositions and method thereof
EP4378953A1 (en) * 2022-12-02 2024-06-05 Universitat de Barcelona Cd229 targeting moiety for the tratment of cd229 positive cancer
WO2025141187A1 (en) * 2023-12-29 2025-07-03 Fundación Para La Investigación Biomédica Del Hospital Universitario 12 De Octubre T cells expressing anti-bcma/anti-cd3 bispecific antibodies and uses thereof
CN122140960B (zh) * 2026-05-11 2026-08-11 重庆医科大学附属第一医院 一种双适配体修饰的膜融合脂质体及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU6827094A (en) 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
NO3051026T3 (da) 2011-10-21 2018-07-28
EP2914628A1 (en) * 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
ES2546743B1 (es) 2014-03-28 2016-07-07 Institut D'investigació Biomèdica De Bellvitge (Idibell) Marcadores mitocondriales de enfermedades neurodegenerativas
BR112016024546A2 (pt) 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
US12048718B2 (en) * 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
CN108004259B (zh) * 2016-11-02 2020-06-30 上海恒润达生生物科技有限公司 靶向b细胞成熟抗原的嵌合抗原受体及其用途
CN108285489A (zh) * 2017-01-09 2018-07-17 上海恒润达生生物科技有限公司 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
AU2019233613B2 (en) 2018-03-13 2025-02-13 Sepsia Therapeutics, S.L. Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes

Also Published As

Publication number Publication date
PL4007777T3 (pl) 2024-03-11
SMT202400013T1 (it) 2024-03-13
EP4007777A1 (en) 2022-06-08
EP4007777B1 (en) 2023-10-11
EP4272837A3 (en) 2024-02-28
EP4272837A2 (en) 2023-11-08
JP7729561B2 (ja) 2025-08-26
HRP20240037T1 (hr) 2024-03-29
LT4007777T (lt) 2024-02-12
PT4007777T (pt) 2024-01-12
SI4007777T1 (sl) 2024-03-29
AU2020325690A1 (en) 2022-03-03
ES2971033T3 (es) 2024-06-03
ZA202201166B (en) 2022-10-26
WO2021023721A1 (en) 2021-02-11
US12509525B2 (en) 2025-12-30
CA3148930A1 (en) 2021-02-11
DK4007777T5 (da) 2024-08-05
RS65094B1 (sr) 2024-02-29
US20220267459A1 (en) 2022-08-25
HUE064890T2 (hu) 2024-04-28
JP2022542443A (ja) 2022-10-03
FI4007777T3 (fi) 2024-01-11

Similar Documents

Publication Publication Date Title
DK3501542T3 (da) Esketamin til behandling af depression
DK3743070T3 (da) Forbindelser til behandling af kinaseafhængige lidelser
DK3728271T3 (da) Makrocykliske forbindelser til behandling af sygdomme
DK3661514T3 (da) Mavacamten til behandling af hypertrofisk kardiomyopati
DK3431105T3 (da) Medicinsk sammensætning til behandling af cancer
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
IL281427A (en) Compounds for treating certain leukemias
DK3402499T3 (da) Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3240538T3 (da) Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose
DK4285929T3 (da) Kombinationsterapi mod hbv
DK4013412T3 (da) Ripretinib til behandling af gastrointestinale stromale tumorer
DK4007777T5 (da) Car-t-celler mod bcma til behandlingen af myelomatose
DK3805220T3 (da) Polycykliske carbamoylpyridon-derivater til behandling af hiv
DK3436074T3 (da) Thiazolidforbindelser til behandling af virale infektioner
DK3573620T3 (da) Sammensætninger til behandling af hypertension
DK3655013T3 (da) Målretning mod synaptogyrin-3 ved behandling af tauopati
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
DK3638293T3 (da) Sammensætninger til behandling af cancer
DK3886799T3 (da) Sammensætninger til behandlingen af hårtab
DK3463328T3 (da) Seladelpar til behandling af primær biliær cholangitis
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
DK3506956T3 (da) Lægemiddel, særlig til behandling af fistler